Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15711MR)

This product GTTS-WQ15711MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15711MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11171MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ1892MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ3023MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ14208MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ14060MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ5751MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ12290MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ5568MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP-771
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW